AU6378099A - A new composition - Google Patents

A new composition

Info

Publication number
AU6378099A
AU6378099A AU63780/99A AU6378099A AU6378099A AU 6378099 A AU6378099 A AU 6378099A AU 63780/99 A AU63780/99 A AU 63780/99A AU 6378099 A AU6378099 A AU 6378099A AU 6378099 A AU6378099 A AU 6378099A
Authority
AU
Australia
Prior art keywords
treatment
component
pharmaceutical formulation
disorders
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU63780/99A
Other languages
English (en)
Inventor
John Evenden
Seth-Olov Thorberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU6378099A publication Critical patent/AU6378099A/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU63780/99A 1998-09-16 1999-09-13 A new composition Abandoned AU6378099A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9803156A SE9803156D0 (sv) 1998-09-16 1998-09-16 A new composition
SE9803156 1998-09-16
PCT/SE1999/001597 WO2000015218A1 (en) 1998-09-16 1999-09-13 A new composition

Publications (1)

Publication Number Publication Date
AU6378099A true AU6378099A (en) 2000-04-03

Family

ID=20412627

Family Applications (1)

Application Number Title Priority Date Filing Date
AU63780/99A Abandoned AU6378099A (en) 1998-09-16 1999-09-13 A new composition

Country Status (21)

Country Link
EP (1) EP1128825A1 (sk)
JP (1) JP2002524508A (sk)
KR (1) KR20010099647A (sk)
CN (1) CN1317964A (sk)
AR (1) AR021808A1 (sk)
AU (1) AU6378099A (sk)
BR (1) BR9913748A (sk)
CA (1) CA2342341A1 (sk)
CZ (1) CZ2001961A3 (sk)
EE (1) EE200100157A (sk)
HU (1) HUP0103544A3 (sk)
ID (1) ID28785A (sk)
IL (1) IL141519A0 (sk)
IS (1) IS5879A (sk)
NO (1) NO20011312L (sk)
PL (1) PL346763A1 (sk)
SE (1) SE9803156D0 (sk)
SK (1) SK3262001A3 (sk)
TR (1) TR200100779T2 (sk)
WO (1) WO2000015218A1 (sk)
ZA (1) ZA200101946B (sk)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60122015T2 (de) * 2000-10-13 2006-11-23 Neurosearch A/S Behandlung affektiver störungen durch kombinierte wirkung eines nikotinischen rezeptoragonisten und einer monoaminergischen substanz
EP1859807A4 (en) * 2005-03-04 2008-04-23 Univ Tokyo Medical & Dental THERAPEUTIC AGENT FOR PREVENTING RECURRENCE OF PSYCHOSTIMULATING INDUCED PSYCHOSIS OR SCHIZOPHRENIA

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9501567D0 (sv) * 1995-04-27 1995-04-27 Astra Ab A new combination

Also Published As

Publication number Publication date
HUP0103544A2 (hu) 2002-05-29
TR200100779T2 (tr) 2001-10-22
HUP0103544A3 (en) 2003-12-29
ZA200101946B (en) 2002-06-10
NO20011312D0 (no) 2001-03-15
NO20011312L (no) 2001-05-16
PL346763A1 (en) 2002-02-25
ID28785A (id) 2001-07-05
IS5879A (is) 2001-03-07
SE9803156D0 (sv) 1998-09-16
EP1128825A1 (en) 2001-09-05
CN1317964A (zh) 2001-10-17
EE200100157A (et) 2002-08-15
CA2342341A1 (en) 2000-03-23
JP2002524508A (ja) 2002-08-06
SK3262001A3 (en) 2001-08-06
CZ2001961A3 (cs) 2001-08-15
BR9913748A (pt) 2001-07-10
AR021808A1 (es) 2002-08-07
IL141519A0 (en) 2002-03-10
WO2000015218A1 (en) 2000-03-23
KR20010099647A (ko) 2001-11-09

Similar Documents

Publication Publication Date Title
US6169098B1 (en) Composition and methods employing it for the treatment of 5-HT-mediated disorders
US8304431B2 (en) Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US20050203130A1 (en) Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
JP4571485B2 (ja) D4および5−ht2aアンタゴニスト、逆アゴニストまたは部分アゴニストの使用
JP2007513052A (ja) セロトニン再取り込み阻害剤およびアゴメラチンの併用。
EP3400940A1 (en) Prophylactic or therapeutic agent for delirium
US6472423B1 (en) Pharmaceutical composition
AU6378099A (en) A new composition
AU6378199A (en) A new composition
AU6378299A (en) A new composition
AU6377999A (en) A new composition
JP4571645B2 (ja) D4および5−ht2aアンタゴニスト、逆アゴニストまたは部分アゴニストの使用
JP2002511408A (ja) 神経疾患のための新しい治療
MXPA01002370A (en) A new composition
MXPA01002543A (en) A new composition
CA2451798C (en) Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted